Who Exports Theophylline from India — 114 Suppliers Behind a $15.7M Market
India's theophylline export market is supplied by 114 active exporters who collectively shipped $15.7M across 1,108 shipments. ALEMBIC PHARMACEUTICALS LIMITED leads with a 23.8% market share, followed by ADCOCK INGRAM LIMITED and ZYDUS LIFESCIENCES LIMITED. The top 5 suppliers together control 70.3% of total export value, reflecting a concentrated market structure.
Top Theophylline Exporters from India — Ranked by Export Value
ALEMBIC PHARMACEUTICALS LIMITED is the leading theophylline exporter from India, holding a 23.8% share of the $15.7M market across 1,108 shipments from 114 exporters. The top 5 suppliers — ALEMBIC PHARMACEUTICALS LIMITED, ADCOCK INGRAM LIMITED, ZYDUS LIFESCIENCES LIMITED, GLENMARK PHARMACEUTICALS LIMITED, MANCARE PHARMACEUTICALS PRIVATE LIMITED — collectively control 70.3% of total export value, indicating a highly concentrated market. Individual shares are: ALEMBIC PHARMACEUTICALS LIMITED (23.8%), ADCOCK INGRAM LIMITED (17.0%), ZYDUS LIFESCIENCES LIMITED (13.4%), GLENMARK PHARMACEUTICALS LIMITED (10.2%), MANCARE PHARMACEUTICALS PRIVATE LIMITED (5.9%).
Top Theophylline Exporters from India
Ranked by export value · 114 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ALEMBIC PHARMACEUTICALS LIMITED THEOPHYLLINE ER TABS 300MG 100T BT AP USTHEOPHYLLINE ER TABS 30MG 100T BT AP USTHEOPHYLLINE TABS NOS | $3.7M | 1 | 23.8% |
| 2 | ADCOCK INGRAM LIMITED NUELIN SR-200MG TABLETS (THEOPHYLLINE ANNUELIN SR-200MG TABLETS THEOPHYLLINE ANNUELIN SR-250MG TABLETS (THEOPHYLLINE AN | $2.7M | 5 | 17.0% |
| 3 | ZYDUS LIFESCIENCES LIMITED DERIPHYLLIN RETARD 150MG TABDERIPHYLLIN RETARD 150 TAB 1X300DERIPHYLLIN RETARD 150MG TAB 1X300 | $2.1M | 4 | 13.4% |
| 4 | GLENMARK PHARMACEUTICALS LIMITED THEOPHYLLINE ER TABS 300MG 100T BT AP USTHEOPHYLLINE ER TABS 30MG 100T BT AP USTHEOPHYLLINE TABS NOS | $1.6M | 1 | 10.2% |
| 5 | MANCARE PHARMACEUTICALS PRIVATE LIMITED FERINOL TABLETFRALIF (SALBUTAMOL AND THEOPHYLLINE TABL | $928.2K | 1 | 5.9% |
| 6 | WATSON PHARMA PRIVATE LIMITED THEOPHYLLINE ER TABS 300MG 100T BT AP USTHEOPHYLLINE ER TABS 30MG 100T BT AP USTHEOPHYLLINE TABS NOS | $518.1K | 1 | 3.3% |
| 7 | ADCOCK INGRAM LTD NUELIN SR-200MG TABLETS (THEOPHYLLINE ANNUELIN SR-200MG TABLETS THEOPHYLLINE ANNUELIN SR-250MG TABLETS (THEOPHYLLINE AN | $443.6K | 2 | 2.8% |
| 8 | CLAROID PHARMACEUTICALS PRIVATE LIMITED FERINOL TABLETFRALIF (SALBUTAMOL AND THEOPHYLLINE TABL | $389.5K | 1 | 2.5% |
| 9 | RECIPHARM PHARMASERVICES PRIVATE LIMITED THEOPHYLLINE ER TABS 300MG 100T BT AP USTHEOPHYLLINE ER TABS 30MG 100T BT AP USTHEOPHYLLINE TABS NOS | $317.2K | 1 | 2.0% |
| 10 | ANNORA PHARMA PRIVATE LIMITED THEOPHYLLINE ER TABS 300MG 100T BT AP USTHEOPHYLLINE ER TABS 30MG 100T BT AP USTHEOPHYLLINE TABS NOS | $290.4K | 1 | 1.8% |
| 11 | SOCOMED PHARMA PRIVATE LIMITED FERINOL TABLETFRALIF (SALBUTAMOL AND THEOPHYLLINE TABLOTHER: RASTHANOL THEOPHYLLINE 100 MG + | $281.1K | 5 | 1.8% |
| 12 | CADILA HEALTHCARE LIMITED DERIPHYLLIN RETARD 150MG TABDERIPHYLLIN RETARD 150 TAB 1X300DERIPHYLLIN RETARD 150MG TAB 1X300 | $260.5K | 2 | 1.7% |
| 13 | STRIDES PHARMA SCIENCE LIMITED THEOPHYLLINE ER TABS 300MG 100T BT AP USTHEOPHYLLINE ER TABS 30MG 100T BT AP USTHEOPHYLLINE TABS NOS | $229.7K | 1 | 1.5% |
| 14 | LAZERHEAD LIFESCIENCES PRIVATE LIMITED THEOSERV XR 250MG THEOPHYLLINE ANHYDRO | $137.0K | 1 | 0.9% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Theophylline exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | 223 | Received multiple FDA approvals between 2024 and 2025; WHO-GMP and EU GMP certif |
| Zydus Lifesciences Limited | Approved | Yes | Yes | Not specified | Formerly Cadila Healthcare; received FDA approval for enzalutamide tablets in Oc |
| Glenmark Pharmaceuticals Limited | Approved | Yes | Yes | Not specified | Received FDA warning letter in July 2025 for Madhya Pradesh facility; WHO-GMP an |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Not specified | EU GMP certified in April 2007; WHO-GMP certified. |
TransData Nexus reviewed the regulatory standing of 4 leading Theophylline exporters from India. 4 hold US FDA facility approvals, 4 maintain WHO-GMP certification, and 4 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Theophylline sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal center for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in API manufacturing. This robust infrastructure positions Hyderabad as a key supplier of Theophylline APIs, ensuring a steady supply chain for both domestic formulation units and international markets.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with companies like Zydus Lifesciences Limited and Alembic Pharmaceuticals Limited headquartered in this region. These companies are among the top exporters of Theophylline, with Alembic Pharmaceuticals Limited accounting for 23.8% of total exports. The region's emphasis on formulations, coupled with a strong regulatory framework, makes it a significant hub for Theophylline tablet production.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. Mumbai, being the financial capital, houses the headquarters of several pharmaceutical giants, including Cipla. The region's well-developed port infrastructure facilitates the export of pharmaceutical products, including Theophylline, to major markets such as the United States, which accounts for 46.5% of India's Theophylline exports. The strategic location and established logistics network make this cluster vital for international distribution.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 manufacturing units. The region's growth has been significantly driven by favorable government policies, including tax incentives that have attracted numerous pharmaceutical companies. Baddi's contribution to the pharmaceutical sector includes the production of various formulations, potentially encompassing Theophylline, thereby supporting both domestic supply and export demands.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Leverage API Strengths: Source Theophylline APIs from Hyderabad-based manufacturers to capitalize on their expertise and production capacity.
- Formulation Partnerships: Collaborate with formulation units in the Ahmedabad-Vadodara region to ensure high-quality finished products.
- Optimize Export Logistics: Utilize the Mumbai-Thane-Raigad corridor for efficient export operations, taking advantage of its established infrastructure and proximity to major ports.
By strategically engaging with these pharmaceutical clusters, companies can enhance their supply chain resilience and ensure a consistent supply of Theophylline to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Theophylline exporters from India
Alembic Pharmaceuticals Limited — Alembic acquires 100% stake in Aleor Dermaceuticals
In March 2025, Alembic Pharmaceuticals Limited completed the acquisition of the remaining stake in Aleor Dermaceuticals Ltd., thereby making it a wholly owned subsidiary. This strategic move aims to enhance Alembic's capabilities in dermatology and related therapeutic areas. - IMPACT: This acquisition is expected to strengthen Alembic's product portfolio, potentially increasing its Theophylline production capacity and export capabilities.
Impact: This acquisition is expected to strengthen Alembic's product portfolio, potentially increasing its Theophylline production capacity and export capabilities.
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business
In July 2025, Zydus Lifesciences Limited acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. This acquisition is part of Zydus' strategy to expand its biologics manufacturing capabilities. - IMPACT: The acquisition may lead to increased production capacity, potentially enhancing Zydus' Theophylline export capabilities.
Impact: The acquisition may lead to increased production capacity, potentially enhancing Zydus' Theophylline export capabilities.
Glenmark Pharmaceuticals Limited — Glenmark transfers consumer care business to new subsidiary
In August 2025, Glenmark Pharmaceuticals announced the transfer of its consumer care business into a newly incorporated, wholly owned subsidiary named Glenmark Consumer Care Limited. This restructuring aims to segregate the marketing and trading of pharmaceutical and consumer care products. - IMPACT: The restructuring allows Glenmark to focus more on its core pharmaceutical operations, potentially enhancing its Theophylline production and export activities.
Impact: The restructuring allows Glenmark to focus more on its core pharmaceutical operations, potentially enhancing its Theophylline production and export activities.
Common Questions — Theophylline Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which theophylline supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ALEMBIC PHARMACEUTICALS LIMITED leads with 10 recorded shipments worth $3.7M. ADCOCK INGRAM LIMITED (92 shipments) and ZYDUS LIFESCIENCES LIMITED (68 shipments) are also established high-volume exporters.
Q How many theophylline manufacturers are there in India?
India has 114 active theophylline exporters with a combined export market of $15.7M across 1,108 shipments to 67 countries. The top 5 suppliers hold 70.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for theophylline from India?
Average FOB unit price: $12.53 per unit, ranging from $0.00 to $178.07. Average shipment value: $14.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 114 verified Indian exporters of Theophylline ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,108 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 67 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,108 Verified Shipments
114 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists